960 San Antonio Road
Palo Alto, CA 94303
United States
650 516 4310
https://www.scilexholding.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 106
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Henry H. Ji Ph.D. | Executive Chairman | 885.43k | N/A | 1964 |
Mr. Jaisim Shah | President, CEO & Director | 971.52k | N/A | 1960 |
Mr. Stephen Ma | Senior VP, CFO & Corporate Secretary | 708.78k | N/A | 1973 |
Dr. Suketu D. Desai Ph.D. | CTO & Senior VP | N/A | N/A | 1966 |
Ms. Gigi DeGuzman | Executive Director of Administrative Operations & Head of Human Resources | N/A | N/A | N/A |
Mr. Steven F. Lincoln J.D. | General Counsel & Chief Compliance Officer | N/A | N/A | N/A |
Mr. Sumant Rajendran | Executive Director of Marketing | N/A | N/A | N/A |
Mike Ciaffi | National Sales Director | N/A | N/A | N/A |
Mr. Suresh K. Khemani | Senior VP & Chief Commercial Officer | 456.82k | N/A | 1960 |
Dr. Dmitri V. Lissin M.D. | Senior VP & Chief Medical Officer | 528.83k | N/A | 1960 |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Scilex Holding Company’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.